Your English writing platform
Discover LudwigExact(57)
The phenotypes are described as ultrarapid, extensive, intermediate, and poor metabolizers.
The Glass model developed in 2003 uses prognostic factors for noncastrate metastatic prostate cancer (NCMPC) to define subgroups with good, intermediate, and poor prognosis.
The International Germ Cell Consensus (IGCC) classification defines good, intermediate, and poor prognosis groups among patients with nonseminomatous germ cell cancer.
The International Prognostic Scoring System (IPSS) identified three critical factors that influence survival and AML evolution: risk-based cytogenetic subgroups (good, intermediate and poor karyotypes), bone marrow blast percentage and the number of cytopenias.
Three of these rivers, exhibiting good, intermediate and poor overall water quality, were the subject of a study in which the effects of contamination on hepatic biomarkers and tissue contaminant loads in feral and caged chub (Leuciscus cephalus) were investigated.
The branches of the clustering tree (patients) were labeled by type of response according to the initial categorization of the early response (marked, intermediate, and poor) [11] (Fig 1).
CYP2D6 intermediate and poor metabolizers with low endoxifen levels may still benefit from higher tamoxifen doses.
Patients in all MSKCC-risk categories (favourable, intermediate and poor) were included.
5-year local relapse-free rates in the good, intermediate and poor prognostic groups were 100%, 42.5% and 9.6%, respectively.
Similar(2)
51, 52 In conclusion, elderly AML patients with intermediate-and poor-risk cytogenetics continue to have a very poor prognosis.
We accepted individual study authors' assessment of prognosis into favorable-risk, intermediate, and poor-risk patients.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com